Tanager Wealth Management LLP Makes New $233,000 Investment in Pfizer Inc. (NYSE:PFE)

Tanager Wealth Management LLP acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 8,045 shares of the biopharmaceutical company’s stock, valued at approximately $233,000.

Several other large investors have also modified their holdings of PFE. International Assets Investment Management LLC purchased a new stake in shares of Pfizer during the third quarter valued at $146,481,000. Heartland Bank & Trust Co lifted its stake in Pfizer by 8.3% during the third quarter. Heartland Bank & Trust Co now owns 23,068 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,777 shares in the last quarter. McAdam LLC boosted its holdings in shares of Pfizer by 13.9% in the third quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 2,628 shares during the period. Guidance Capital Inc. increased its position in shares of Pfizer by 2.1% in the third quarter. Guidance Capital Inc. now owns 34,886 shares of the biopharmaceutical company’s stock worth $1,019,000 after acquiring an additional 706 shares in the last quarter. Finally, Greenleaf Trust raised its holdings in shares of Pfizer by 4.2% during the third quarter. Greenleaf Trust now owns 297,265 shares of the biopharmaceutical company’s stock valued at $8,603,000 after acquiring an additional 11,935 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 0.1 %

Pfizer stock opened at $28.86 on Thursday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The firm’s fifty day simple moving average is $29.07 and its 200-day simple moving average is $28.48. The company has a market capitalization of $163.54 billion, a P/E ratio of -481.00, a P/E/G ratio of 1.02 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $0.67 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. Pfizer’s payout ratio is currently -2,800.00%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.